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Melusin is a chaperone protein selectively expressed in heart and skeletal muscles.
Melusin expression levels correlate with cardiac function in pre-clinical models and in
human patients with aortic stenosis. Indeed, previous studies in several animal models
indicated that Melusin plays a broad cardioprotective role in different pathological
conditions. Chaperone proteins, besides playing a role in protein folding, are also
able to facilitate supramolecular complex formation and conformational changes due
to activation/deactivation of signaling molecules. This role sets chaperone proteins as
crucial regulators of intracellular signal transduction pathways. In particular Melusin
activates AKT and ERK1/2 signaling, protects cardiomyocytes from apoptosis and
induces a compensatory hypertrophic response in several pathological conditions.
Therefore, selective delivery of the Melusin gene in heart via cardiotropic adenoviral
associated virus serotype 9 (AAV9), may represent a new promising gene-therapy
approach for different cardiac pathologies.
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ROLE OF CHAPERONES AND CO-CHAPERONES IN THE
STRESSED HEART
Proteins are synthesized as linear amino acid chains that must fold in a specific three-dimensional
structure and maintain their functional conformation to carry out their biological functions
(Balchin et al., 2016). However, the preservation of a particular fold depends on different
factors, including temperature, pH, protein-protein interactions, post-translational modifications,
mechanical stretch, etc. Moreover, in several cases, proteins need to change conformation to
accomplish their functions. For instance, extracellular ligands, by binding to membrane receptors,
are able to trigger a cascade of conformational changes in cytoplasmic signal transduction proteins.
During structural switches, proteins pass through metastable intermediates exposing hydrophobic
amino acid residues, potentially causing toxic protein aggregates. Cells evolved an organized
chaperone system to cope with misfolding of native proteins and assist physiological protein
conformational changes and unfolding emergencies.
The highly specialized sarcomeric structures in cardiomyocytes consist of a number of proteins
bound to each other in a very regulated fashion, creating a dense protein matrix. Mechanical
overload is sensed by membrane receptors connecting the extracellular matrix to the intracellular
cytoskeleton, like integrins (Brancaccio et al., 2006). Growing evidence indicates that excessive
mechanical stretch, such as the ones induced by hypertension, aortic stenosis, myocardial
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infarction, etc., induces protein misfolding (Willis and Patterson,
2010; Tarone and Brancaccio, 2014; McLendon and Robbins,
2015; Parry et al., 2015). Moreover, mechanical stretch and
humoral factors released in response to excessive workload
activate signal transduction pathways (Tarone and Lembo,
2003) that need to be assisted by chaperones to properly
sustain cell survival and induce cardiomyocyte hypertrophic
growth. Unfolded proteins, by exposing hydrophobic amino
acid stretches, are prone to form insoluble toxic aggregates
in cardiomyocytes, potentially contributing to cell death (Del
Monte and Agnetti, 2014; Parry et al., 2015). Accordingly,
patients suffering from hypertrophic cardiomyopathy and
idiopathic dilated cardiomyopathy accumulate misfolded
proteins in the heart (Parry et al., 2015).
Chaperone proteins are characterized by different molecular
weight, subcellular localization and enzymatic activity. In
response to stressful conditions, chaperone expression is induced
in cardiomyocytes to cope with the unfolding emergency.
However, if stress conditions persist, chaperone activity
becomes insufficient for protecting cells form proteotoxicity,
and pathological remodeling takes place (Del Monte and
Agnetti, 2014). Several chaperones have been described to
build a compensatory response in the stressed heart in a
cooperative manner (Willis and Patterson, 2010; Tarone and
Brancaccio, 2014). HSP90 is one of themost important molecular
chaperones, acting as a dynamic dimer that switches through
multiple conformations. Co-chaperones regulate HSP90 ATPase
activity, interact with further components of the machinery
and drive substrate binding (Li et al., 2012; Verma et al., 2016).
HSP90 interacts with a variety of substrates also called “HSP90
client proteins” among them transcription factors, signaling
molecules, apoptosis regulators, and cytoskeletal components
(http://www.picard.ch/downloads/downloads.htm), controlling
their activity and degradation. It is thus conceivable that Hsp90
plays multiple important roles in sustaining heart function
upon stress adaptation, by inducing protein refolding, directing
unfolded proteins to proteasome degradation, and assisting
conformational changes in signal transduction molecules (Ficker
et al., 2003; Kupatt et al., 2004; Tarone and Brancaccio, 2014;
Parry et al., 2015).
A second class of chaperones, the small heat shock
proteins (sHsps) family, is devoid of ATPase activity and
characterized by an α-crystallin domain responsible for their
oligomerization. The association between sHsp oligomers and
client proteins is required for their anti-aggregation activity
(Vos et al., 2011; Bakthisaran et al., 2015; Haslbeck and
Vierling, 2015). sHsps show anti-apoptotic activity, inhibit
misfolded protein aggregation, mediate protein refolding in
cooperation with Hsp90, and regulate signal transduction
pathways (Vos et al., 2008, 2011; Bakthisaran et al., 2015).
Growing experimental evidence indicates a role for this class
of chaperones in sustaining heart function in stress conditions
(Willis and Patterson, 2010; Tarone and Brancaccio, 2014; Parry
et al., 2015). For instance, αB-crystallin protects the heart
from ischemia/reperfusion injury and, when overexpressed, it
attenuates cardiac hypertrophy caused by pressure overload.
Moreover, missense mutations in the αB-crystallin coding gene
cause a desmin related cardiomyopathy (Boelens, 2014; Anbarasu
and Sivakumar, 2016). Hsp27, another chaperone expressed in
the heart, protects from ischemia/reperfusion damage when
overexpressed (Christians et al., 2012). Hsp20 also displays
a well-documented cardioprotective activity by enhancing
cardiomyocyte survival and improving heart contractility in
different models of heart failure (Fan and Kranias, 2011; Martin
et al., 2014).
In this review we will focus on the cardioprotective role of the
muscle specific chaperone protein Melusin, showing both Hsp90
co-chaperone function and typical features of sHsps.
MELUSIN STRUCTURE AND CHAPERONE
FUNCTION
Melusin is a chaperone protein, encoded by the ITGB1BP2 gene,
expressed selectively in heart and skeletal muscles. Melusin has
been identified as an interactor of the cytoplasmic region of
β1 integrin (Brancaccio et al., 1999), a membrane receptor that
connects the intracellular cytoskeleton with the extracellular
matrix, allowing muscle cells to respond to mechanical stimuli
(Brancaccio et al., 2006). This chaperone protein shows a highly
conserved structure in vertebrates, consisting of two Cysteine
and Histidine-Rich Domains (CHORDS), a CS domain, shared
by CHORD proteins and by the co-chaperone protein Sgt1
(Shirasu et al., 1999), and a C-terminal Ca2+-binding domain,
enriched in aspartic and glutamic acid residues (Brancaccio
et al., 1999). CHORD I-II domains in the amino-terminal region
of Melusin are 60-amino acid zinc-binding domains, highly
conserved during evolution and able to mediate the binding of
Melusin to HSP90 (Hahn, 2005; Sbroggiò et al., 2008; Hong
et al., 2013). Moreover, the CS domain, structurally similar to
α-crystallin and p23 chaperone proteins (Garcia-Ranea et al.,
2002), has also been described as an HSP90 binding module
(Lee et al., 2004; Zhang et al., 2010). Melusin, through its
CHORD domains, directly binds the ATPase domain of HSP90
(Sbroggiò et al., 2008) preferentially in its ADP-bound state
(Gano and Simon, 2010; Zhang et al., 2010; Hong et al., 2013).
In addition, the binding of Ca2+ to the C-terminal domain
of Melusin enhances its interaction with HSP90 (Hong et al.,
2013). This is particularly relevant considering the crucial role
of Ca2+ ions in muscle contraction and the link between
heart failure and Ca2+ cycling dysfunction in cardiomyocytes
(Marks, 2013). Interestingly, Melusin inhibits denatured protein
aggregation in vitro in a dose dependent manner, showing a
potential intrinsic chaperone activity (Sbroggiò et al., 2008), and
displays the ability to oligomerize (Hong et al., 2013), a feature
correlated with increased chaperone activity in small heat shock
proteins (Garrido et al., 2012; Bakthisaran et al., 2015; Haslbeck
and Vierling, 2015). These are relevant functions considering
the accumulation of toxic misfolded proteins occurring during
cardiomyopathy (Willis and Patterson, 2013; Del Monte and
Agnetti, 2014; Tarone and Brancaccio, 2014). However, it is
noteworthy that the ability of Melusin to act as a chaperone is
based only on in vitro experiments and further evidences are
required to confirm this property in vivo.
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MELUSIN CARDIOPROTECTIVE ROLE IN
ANIMAL MODELS OF CARDIOMYOPATHY
The protective role of Melusin in the heart is strictly related to the
cardiac response to stress stimuli. Upon mechanical stretch, the
heart activates a compensatory hypertrophic response, causing an
increase in the thickness of the left ventricle wall that preserves
contractility. However, if the stimulus becomes chronic, the heart
undergoes a pathological evolution from adaptive hypertrophy to
dilated cardiomyopathy with loss of contractile function, known
as “maladaptive remodeling.”
In a mouse model subjected to cardiac mechanical stretch
via surgical aortic banding, mimicking human pathologies such
as chronic aortic stenosis, left ventricle outflow obstruction, or
systemic hypertension, Melusin expression levels increase in left
ventricles in the first week of pressure overload, during the
induction of the compensatory hypertrophic response (De Acetis
et al., 2005; Sbroggiò et al., 2008). However, Melusin expression
decreases when chamber dilation and loss of contractility ensues
(De Acetis et al., 2005). Notably, this correlation betweenMelusin
expression levels and cardiac response to stress has been reported
also in a dog model of volume overload (Donker et al., 2007).
Another pathological condition characterized by maladaptive
remodeling in humans is the myocardial infarction (Heusch
et al., 2014). The occlusion of coronary arteries induces an
ischemic insult to the cardiac tissue in which the damaged
area is replaced by a non-contractile connective scar and the
healthy portion undergoes hypertrophy because of increased
hemodynamic stress. In a rat model of myocardial infarction
obtained by permanent coronary ligation, analysis at different
time points after the ischemic injury revealed a direct correlation
betweenMelusin expression and the rates of left ventricle systolic
pressure and fractional shortening (Gu et al., 2012).
To investigate the specific role of Melusin in protecting
myocardium from adverse remodeling in vivo, Melusin-nullmice
(Brancaccio et al., 2003) and transgenic mice overexpressing
Melusin in cardiomyocytes (De Acetis et al., 2005) have been
generated. Melusin-null mice are healthy and fertile under
normal conditions and they do not display obvious defects
in striated muscle development and structure. These mice
show normal myocardial parameters (Brancaccio et al., 2003),
indicating that Melusin is not crucial for cardiac development
and basal physiological functions. However, the cardioprotective
role of Melusin becomes evident under mechanical stress
conditions. Whereas wild-type mice activate a compensatory
hypertrophic response after 4 weeks following aortic stenosis,
Melusin-null mice fail to activate this program and rapidly
develop a dilated cardiomyopathy with left ventricle dilation,
chamber wall thinning, and impaired contractility (Brancaccio
et al., 2003).
The importance of Melusin in the cardiac response to
mechanical stretch has been further confirmed by analyzing
Melusin overexpressing mice. In basal conditions, these mice
show a mild cardiomyocyte hypertrophy without alteration of
contractile function (De Acetis et al., 2005). Instead, upon
pressure overload conditions, Melusin overexpression effectively
protects mouse myocardium by sustaining the compensatory
hypertrophic response and healthy contractile function even after
12 weeks of aortic banding, when wild-type mice have already
developed a dilated cardiomyopathy and heart failure (De Acetis
et al., 2005).
During maladaptive remodeling of the heart, cardiomyocyte
loss, inflammation, deposition of fibrotic tissue, and reduction
of capillary density typically occur. Notably, Melusin
overexpression protects cardiomyocytes from apoptotic
death, reduces inflammation and stromal tissue deposition and
stimulates capillary growth (De Acetis et al., 2005; Figure 1).
In mice overexpressing Melusin in which myocardial
infarction is induced by permanent left descending coronary
ligation, Melusin ensures a double protective role. In the early
phase, it reduces the inflammatory response and protects against
cardiac rupture; in long term recovery it prevents the heart
from dilated degeneration by improving cardiomyocyte survival
(Unsold et al., 2014).
Upon acute coronary occlusion, the duration of the ischemia
determines the extent of cardiac damage. In clinical practice,
acute myocardial infarction is treated with angioplasty or
thrombolysis to induce a prompt coronary re-opening. However,
sudden re-oxygenation determines the so-called “reperfusion
injury,” characterized by the production of reactive oxygen
species, calcium overload, and the opening of the mitochondrial
permeability transition pore, which all cause cardiomyocyte
death and subsequent inflammation, thereby worsening the
initial ischemic damage (Yellon and Hausenloy, 2007; Perrelli
et al., 2011). The ischemia-reperfusion injury is well-reproduced
in isolated perfused hearts with the Langendorff technique. In
this model, Melusin overexpression significantly reduces the
infarct size area and cardiomyocyte cell death, thus protecting the
heart from ischemia-reperfusion injury (Penna et al., 2014).
MELUSIN IN HUMAN
CARDIOMYOPATHIES
A link between Melusin expression and cardiac functional
parameters has also been observed in humans. In a cohort
FIGURE 1 | Melusin cardioprotective role in the heart. Melusin protects
the heart from "maladaptive remodeling" during mechanical stress. Melusin
potentiates the compensatory hypertrophic response of the heart preserving
its contractile function. Melusin also prevents cardiac dilation and fibrosis
deposition and protects cardiomyocytes from apoptotic death.
Frontiers in Molecular Biosciences | www.frontiersin.org 3 September 2016 | Volume 3 | Article 53
Sorge and Brancaccio Melusin Protects Heart under Stress
of 17 patients with aortic stenosis evolved to severe heart
failure, Melusin expression positively correlates with left ventricle
ejection fraction (Brokat et al., 2007). A genetic screening for
Melusin mutations in cardiomyopathic patients, performed by
three independent laboratories, have revealed two missense
mutations, a His13Tyr mutation in the CHORD I domain in
a family with hypertrophic cardiomyopathy (Palumbo et al.,
2009), and an Ala313Gly mutation in the carboxy terminal
region linking the CS domain to the acidic domain in a family
with dilated cardiomyopathy (Ruppert et al., 2013) but their
segregation in the family members not always correlates with
the onset of cardiomyopathy, making their causative significance
unclear. Furthermore, structural analysis on the Melusin
homolog in plants suggests that His13Tyr mutation does not
disrupt the interaction with Hsp90 and that Ala313Gly mutation
is distant from known CS domain interaction sites (Zhang et al.,
2010). Another silent mutation, an intronic duplication and some
polymorphisms has also been found in a study of population
screening comparing cardiopathic and healthy subjects (Palumbo
et al., 2009). However, all these analyses led to the consideration
thatMelusin gene (ITGB1BP2) mutations are very rare within the
population, with no significant relevance in the epidemiology of
cardiomyopathy. On the other hand, pre-clinical studies indicate
that the regulation of Melusin expression may play a key role in
improving the ability of the myocardium to cope with different
stressors.
MELUSIN CARDIOPROTECTIVE SIGNAL
TRANSDUCTION
Mechanical stress induces in the heart the activation of specific
signal transduction pathways and the release of neurohumoral
mediators acting on cardiomyocytes, fibroblasts and endothelial
cells, regulating the heart’s response to stress. The balance
between these signals may direct the overall cardiac response
to a compensatory or to a maladaptive remodeling (Tarone and
Lembo, 2003). Extensive data indicate that the activation of the
MAPK andAKT signal transduction pathways in cardiomyocytes
promotes cell survival and compensatory hypertrophic growth,
protecting the heart from dilation and failure (Selvetella et al.,
2004; Baines andMolkentin, 2005; Tarone et al., 2013). Molecular
analysis of the myocardial signaling pathways, indicate that
Melusin interacts with several signaling molecules, including
the Focal Adhesion Kinase (FAK), the MAPK scaffold protein
IQGAP1, the mitogen activated protein kinases c-Raf, MEK1/2,
and ERK1/2 (Sbroggiò et al., 2011a) and the phosphoinositide
3-kinases (PI3Ks), which in turn activate AKT (Waardenberg
et al., 2011). We demonstrated a role for the Focal adhesion
kinase in activating Melusin-bound ERK1/2 in response to
mechanical stretch (Sbroggiò et al., 2011a). The Melusin
binding protein IQGAP1 is a scaffold protein able to bind c-
Raf, MEK1/2, and ERK1/2 and to facilitate their sequential
phosphorylation. Accordingly, IQGAP1 is essential for the
activation of the MAPK pathway in response to Melusin
overexpression and pressure overload in vivo (Sbroggiò et al.,
2011a,b).
These data suggest that Melusin, along with Hsp90,
mediates the assembly of a signalosome organized on
the scaffold protein IQGAP1 to activate and integrate
beneficial ERK1/2 signaling (Tarone et al., 2013) with the
AKT pathway (Figure 2). In accordance, a role for Hsp90 in
promoting and maintaining the assembly of protein complexes
has been previously described (Makhnevych and Houry,
2012).
Melusin, indeed, potentiates ERK1/2 and AKT
phosphorylation in transgenic mice subjected to transverse
aortic constriction, preventing the evolution to dilated
cardiomyopathy (Brancaccio et al., 2003; De Acetis et al.,
2005). In the model of myocardial infarction due to permanent
coronary ligation, Melusin overexpression significantly enhances
ERK1/2 phosphorylation at the myocardial infarct border zone,
where mechanical stretch is higher, reducing the extent of the
damage (Unsold et al., 2014). Furthermore, the activation of the
reperfusion injury salvage kinase (RISK) pathway, composed by
the PI3K/AKT and the ERK1/2 pathways, has been shown to
protect cardiomyocytes during the reperfusion phase (Hausenloy
and Yellon, 2004). This pathway is required for Melusin
protective role in the ischemia/reperfusion model, since their
pharmacological inhibition abrogates Melusin protection (Penna
et al., 2014). Notably, in the pathological heart, when Melusin
expression is decreased, also the ERK1/2 and AKT compensatory
pathways are downregulated, allowing the establishment of
detrimental signaling that further impact on heart function (De
Acetis et al., 2005).
CONCLUSION AND THERAPEUTIC
PERSPECTIVES
Melusin is a chaperone protein selectively expressed in cardiac
and skeletal muscles, indicating a tissue specific function for this
protein. Accordingly, its expression is upregulated in response to
mechanical overload in the heart during the hypertrophic phase
(De Acetis et al., 2005; Sbroggiò et al., 2008). Melusin protective
activity in these conditions has been widely demonstrated
in a number of preclinical models (Brancaccio et al., 2003;
De Acetis et al., 2005; Penna et al., 2014; Unsold et al.,
2014) and associated with its ability to build a supramolecular
complex activating ERK1/2 and AKT beneficial pathways in
cardiomyocytes (Sbroggiò et al., 2011a,b). In this view, increasing
Melusin expression in the heart may represent a new therapeutic
approach in cardiomyopathic patients. To date, adeno-associated
viruses (AVVs) are the most promising viral vectors for gene
therapy, also approved by FDA for human clinical trials. AAVs
ensure a stable and efficient transgene expression even in
non-proliferating cells and, once in the human body, do not
induce a significant immune response or insertional mutagenesis
risk (Ponnazhagan et al., 1997; Chirmule et al., 1999). In
particular adenoviral associated virus serotype 9 (AAV9) is able
to direct transgene expression in cardiomyocytes, representing
a promising vector for gene therapy in cardiac diseases. In our
laboratory, an AAV9 virus carrying human Melusin cDNA, able
to induce Melusin expression selectively in the heart is currently
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FIGURE 2 | Melusin-dependent activation of ERK1/2 and AKT under mechanical stress. Under mechanical stretch condition, Melusin binds to the
cytoplasmic domain of β1-integrin and interacts with IQGAP1, leading to the activation of ERK1/2 and AKT cardioprotective pathways.
under investigation for its ability to counteract cardiomyopathy
in different mouse models.
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